An interventional study of ABLE Exoskeleton in Multiple Sclerosis, sponsored by ABLE Human Motion S.L.. Completed at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by ABLE Human Motion S.L. · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.
Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 186th largest by enrollment of the 202 interventional ones that give a count, is one of 25 that started in 2025, is one of 68 with no phase, and was the 197th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:
Clarity Health Technologies, Inc · Sites in Spain
Ages 18–65
Sanofi · Sites in Spain, United States, Belgium and 4 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in Spain, United States, Argentina and 33 more countries
Ages 18–65
Hasselt University · Sites in Spain, Belgium, Italy
Ages 18–65 · Healthy volunteers
Hoffmann-La Roche · Sites in Spain, Argentina, Brazil and 4 more countries
Ages 10–17
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 47 · Phase 3 65 · Phase 4 17
First in 2002; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 137 across the 202 interventional studies, 360 across the 28 observational. Of the 163 that completed or were terminated, 80 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
142 of 230 have an industry lead sponsor. The 10 most frequent:
ABLE Human Motion S.L. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
ABLE Human Motion S.L. has 3 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
13 of the studies in Multiple Sclerosis with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT07735325University of SalamancaEffects of Sensorimotor Insoles on Stability and Gait in Patients With Multiple Sclerosis. | 2026-12 |
| NCT07152145Parc de Salut MarPilot Study of tSCS for Improving Upper Limb Function in People With Multiple Sclerosis | 2026-12 |
| NCT06968676Universidad Rey Juan CarlosMixed Reality for Upper Limb Rehabilitation in People With Multiple Sclerosis (VIRTUALDOMUS) | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 230 studies in Multiple Sclerosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to explore the potential clinical benefits of the ABLE Exoskeleton as part of a rehabilitation program in people with multiple sclerosis. The main question it aims to answer is:
Can a rehabiliation program with the ABLE Exoskeleton help to mantain the physical and psychosocial health of people with multiple sclerosis?
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo 60-min gait training sessions with the exoskeleton as part of their rehabilitation program once a week for up to 12 months
Device: ABLE Exoskeleton
Participants will undergo 60-min gait training sessions with the exoskeleton once a week for up to12 months
Number of therapeutic objectives achieved
Two therapeutic objectives per participant will be defined at baseline. At the end of the training program, it will be assessed if the objectives were accomplished or not.
Time frame: From baseline to the end of the training program at 12 months
Lower extremity muscle strenght
The Daniels Muscle Testing scale will be used to measure the strength of muscles in the lower extremities at baseline, every 3 months and at the end of the gait training program to assess motor function after the training. Scores range from 0 (absence of muscle activity) to 5 (normal muscle activity)
Time frame: Baseline, 3, 6, and 12 months post-training
Modified Ashworth Scale (MAS)
The Modified Ashworth Scale (MAS) measures spasticity in patients with lesions to the central nervous system. The scale assigns a grade of spasticity from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension). It will be evaluated at baseline, every 3 months and at the end of the gait training program without the device to assess the change in the spasticity after training
Time frame: Baseline, 3, 6, and 12 months post-training
Location and level of pain
The location and level of pain using the numeric rating scale (NRS) will be assessed at baseline, every 3 months and at the end of the gait training program to assess the reduction of pain aftr the training
Time frame: Baseline, 3, 6, and 12 months post-training
Timed 25-Feet Walk test (T25FW)
The Timed 25-Foot Walk (T25FW) test measures the time a person needs to walk 25 feet. This test will be assessed at baseline, every 3 months, and at the end of the gait training program without the device to assess the change in the walking function after the training
Time frame: Baseline, 3, 6, and 12 months post-training
6-Minute Walk Test (6MWT)
The 6-Minute Walk Test (6MWT) measures the distance a person can walk in 6 minutes. This test will be assessed at baseline, every 3 months, and at the end of the gait training program without the device to assess the change in the walking function after the training
Time frame: Baseline, 3, 6, and 12 months post-training
Borg Rating of Perceived Exertion
The Borg Rating of Perceived Exertion (RPE) scale is used to measure a person's perception of their effort and exertion, breathlessness, and fatigue during physical activity. Scores range from 6 (no exertion at all) to 20 (maximal exertion). It will be evaluated during the 6MWT at baseline, every 3 months, and after the end of the gait training program without the device to assess the change in the perceived exertion after the training
Time frame: Baseline, 3, 6, and 12 months post-training
Trunk Impairment Scale (TIS)
The Trunk Impairment Scale (TIS) measures the motor impairment of the trunk through the evaluation of static and dynamic sitting balance as well as coordination of trunk movement. The total score ranges from 0 (minimal performance) to 23 (perfect performance). This test will be assessed at baseline, every 3 months, and at the end of the gait training program without the device to assess the change in the trunk impairment after training
Time frame: Baseline, 3, 6, and 12 months post-training
Barthel Index (BI) score
The Barthel Index (BI) will be used to assess the participants' ability to perform mobility and self-care activities of daily living (ADL). The total score ranges from 0 (total dependency) to 100 (independency). It will be evaluated at baseline, every 3 months, and after the gait training program without the device to assess the change in the independence to perform ADL after the training
Time frame: Baseline, 3, 6, and 12 months post-training
Modified Fatigue Impact Scale (MFIS) score
The Modified Fatigue Impact Scale (MFIS) provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning in persons with multiple sclerosis. The total score ranges from 0 to 84, with higher scores meaning a higher impact of fatigue. It will be evaluated iat baseline, every 3 months and at the end of the gait training program without the device to assess the change in the fatigue after the training
Time frame: Baseline, 3, 6, and 12 months post-training
Multiple Sclerosis Quality of Life-54 (MSQoL-54) scores
The Multiple Sclerosis Quality of Life-54 (MSQoL-54) is a multidimensional health-related quality of life (QoL) measure that combines both generic and MS-specific items into a single instrument. There is no single overall score for the MSQoL-54. Two summary scores - physical health and mental health - can be derived from a weighted combination of scale scores. The higher the score, the best the outcome. It will be evaluated at baseline, every 3 months and at the end of the gait training program without the device to assess the change in the QoL after the training
Time frame: Baseline, 3, 6, and 12 months post-training
Self-perceived impact on general health status
Participants' perceptions of the impact on their general health will be evaluated by the completion of a self-report questionnaire on the perceived impact on general health. This questionnaire has been designed by the researchers and intends to identify to what extent participants feel that the ABLE Exoskeleton contributed to a change in their health. The questionnaire covers 7 categories (cardiovascular system, musculoskeletal pain, neuropathic pain, bladder and bowel, spasticity, and sleep quality) using a 7-point Likert scale to assess the change.
Time frame: 3, 6, and 12 months post-training
Level of motivation
Participants' perceptions on the level of motivation generated by the program with the ABLE Exoskeleton will be evaluated by the completion of a self-report questionnaire using a 7-point Likert scale. This questionnaire has been designed by the researchers.
Time frame: After 12 months post-training
Psychosocial Impact of Assistive Devices Scale (PIADS) score
The Psychosocial Impact of Assistive Devices Scale (PIADS) is a 26-item, self-reported questionnaire that provides a measure of user perception and other psychological factors associated with assistive technology devices. Scores range from -78 (maximum negative impact) to +78 (maximum positive impact). It will be used to assess the effects of the ABLE Exoskeleton on functional independence, well-being, and quality of life of participants after the training program experience
Time frame: After 12 months post-training
Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) score
The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) is a 12-item outcome measure that assesses user satisfaction with two components (Device and Services) using a 5-point scale ranging from 1 (not satisfied) to 5 (very satisfied). Only the 8 items referred to the device will be evaluated from participants and the whole 12 items from the therapists to measure user satisfaction with the ABLE Exoskeleton after the training program experience
Time frame: After 12 months post-training
Time spent upright and time spent walking
In each gait training session, the time spent upright (in minutes) and the time spent walking (in minutes) with the device will be automatically measured and registered by the device
Time frame: At session 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10
Number of steps walked
In each gait training session, the number of steps taken (step count) with the device will be automatically measured and registered by the device
Time frame: At session 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10
Distance walked
In each gait training session, the distance walked (in meters) with the device will be automatically measured and registered by the device
Time frame: At session 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in May 2026, 13 months.
Of 874 interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ABLE Human Motion S.L.